Financials data is unavailable for this security.
View more
Year on year Hikma Pharmaceuticals PLC had little change in net income (from 431.00m to 421.00m) despite revenues that grew 9.06% from 2.34bn to 2.55bn. A contributing factor has been an increase in the cost of goods sold as a percent of sales from 48.18% to 49.04%.
| Gross margin | 50.96% |
|---|---|
| Net profit margin | 16.45% |
| Operating margin | 23.42% |
| Return on assets | 9.87% |
|---|---|
| Return on equity | 18.35% |
| Return on investment | 13.05% |
More ▼
Cash flow in USDView more
In 2021, Hikma Pharmaceuticals PLC increased its cash reserves by 31.89%, or 103.00m. The company earned 638.00m from its operations for a Cash Flow Margin of 24.99%. In addition the company used 238.00m on investing activities and also paid 287.00m in financing cash flows.
| Cash flow per share | 2.07 |
|---|---|
| Price/Cash flow per share | 7.96 |
| Book value per share | 8.69 |
|---|---|
| Tangible book value per share | 5.53 |
More ▼
Balance sheet in USDView more
| Current ratio | 2.06 |
|---|---|
| Quick ratio | 1.38 |
| Total debt/total equity | 0.3449 |
|---|---|
| Total debt/total capital | 0.2554 |
More ▼
Growth rates in USD
Year on year, growth in dividends per share increased 8.70% while earnings per share excluding extraordinary items fell by -0.22%. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.02% |
|---|---|
| Div growth rate (5 year) | 11.07% |
| Payout ratio (TTM) | 29.69% |
| EPS growth(5 years) | 22.23 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | -0.2268 |
More ▼
